Sanofi SNY reported first-quarter 2026 adjusted earnings of $1.10 per American depositary share, which beat the Zacks Consensus Estimate of $1.06 per share. Earnings of \u20ac1.88 per share rose 5% on a reported basis and 14.0% on a constant currency rate (\u201cCER\u201d) basis, driven by cost control.<\/p>\n
Net sales rose 6.2% on a reported basis to $12.3 billion (\u20ac10.51 billion). Sales rose 13.6% on a CER basis. Sales beat the Zacks Consensus Estimate of $11.99 billion.<\/p>\n
Sales rose 26.2% at CER in the United States, 0.2% in the Rest of the World (including China, Japan, Brazil and Russia) and 5.9% in Europe.<\/p>\n
All growth rates mentioned below are on a year-on-year basis and at CER.<\/p>\n
SNY\u2019s Dupixent Continues to Outperform <\/p>\n
In Immunology, blockbuster drug Dupixent generated sales of \u20ac4.17 billion in the quarter, up 30.8% year over year, driven by strong prescription trends across all approved indications and geographies.<\/p>\n
Sales of the drug in the United States rose 35.9%. Dupixent sales rose 22.4% in Europe and 14.9% in the Rest of the World.<\/p>\n
Sanofi markets Dupixent in partnership with Regeneron REGN. While sales are recorded by Sanofi, Regeneron records its share of profits\/losses in connection with global sales of Dupixent.<\/p>\n
SNY\u2019s Rare Disease Drugs\u2019 Performance <\/p>\n
Among Sanofi\u2019s rare disease drugs, the rare blood disorder drug, Altuviiio, a once-weekly new class of factor VIII therapy for hemophilia A, recorded sales of \u20ac325 million in the first quarter, up 42.2% year over year, mainly driven by patient switches in the U.S. hemophilia A market and launch in Japan and Taiwan. As much as 83% of Altuviiio\u2019s sales were in the United States.<\/p>\n
Among the rare disease drugs in the Pompe franchise, Nexviazyme\/Nexviadzyme recorded sales of \u20ac208 million, up 13.3% year over year, mainly driven by strong sales growth in Europe. Myozyme sales declined 13.3% year over year to \u20ac112 million due to patients switching to Nexviazyme. Fabrazyme sales were \u20ac265 million, up 7.6% year over year. In the Gaucher franchise, Cerezyme sales rose 1.1% year over year to \u20ac186 million.<\/p>\n
Cablivi recorded sales of \u20ac68 million, up 9% year over year, driven by patient growth in the United States and Europe.<\/p>\n
Among the rare blood disorder drugs, Eloctate sales declined 7.1% to \u20ac58 million in the quarter due to patients switching to the new drug Altuviiio.<\/p>\n
Xenpozyme recorded sales of \u20ac63 million in the quarter, up 17.9% year over year.<\/p>\n
New drug Qfitlia (fitusiran) generated \u20ac5 million in sales, compared with \u20ac4 million in the previous quarter.<\/p>\n
Another new drug, Wayrilz (rilzabrutinib) generated \u20ac10 million in sales in the first quarter versus \u20ac6 million in the previous quarter.<\/p>\n
Story Continues <\/p>\n
Ayvakit, added from last year\u2019s acquisition of Blueprint Medicines, recorded sales of \u20ac177 million compared with \u20ac168 million in the previous quarter, driven by continued patient growth. Higher government rebates hurt U.S. sales to an extent.<\/p>\n
SNY\u2019s Oncology & Other Drugs <\/p>\n
In Oncology, Sarclisa sales rose 30.1% year over year to \u20ac167 million, driven by increased use in earlier lines of treatment in Europe and strong growth from Rest of World.<\/p>\n
In Others, Toujeo recorded sales of \u20ac375.0 million, up 10.5% year over year, driven mainly by volume growth and market share gains in the United States and Europe. Lantus sales declined 0.7% to \u20ac419 million. Rezurock recorded sales of \u20ac133 million, up 11.5% year over year. Tzield sales were \u20ac14 million in the quarter, up 36.4% year over year, driven mainly by U.S. sales.<\/p>\n
Plavix sales declined 3.3% to \u20ac224 million. Lovenox sales decreased 22.3% to \u20ac184 million.<\/p>\n
Heplisav-B Added from Dynavax Deal Boosts SNY\u2019s Vaccine Sales <\/p>\n
Total vaccine sales rose 2.1% to \u20ac1.29 billion, mainly due to higher sales of Sanofi and partner AstraZeneca\u2019s AZN respiratory syncytial virus or RSV antibody, Beyfortusand Polio\/Pertussis\/Hib (PPH) vaccines.<\/p>\n
Sales of PPH vaccines rose 4.2% year over year to \u20ac664 million, gaining from the inclusion of the newly acquired adult hepatitis B vaccine, Heplisav-B, from the acquisition of Dynavax, which closed in February. Sales of meningitis, travel and other endemic vaccines declined 2.0% year over year to \u20ac278 million in the quarter. Sales of flu vaccines declined 4.1% year over year to \u20ac67 million.<\/p>\n
AstraZeneca-partnered Beyfortus recorded sales of \u20ac284 million in the quarter, up 2.8% year over year. Gains from expanded geographical availability in Europe and Rest of the World were partially offset by softer sales in the United States due to a tough comparison from inventory increase in the year-ago quarter.<\/p>\n
SNY Maintains 2026 Guidance <\/p>\n
Sanofi maintained its previously issued financial outlook for 2026.<\/p>\n
Sanofi expects sales to rise by a high single-digit percentage at CER. Sanofi expects earnings to grow faster than sales in 2026 at CER, before the impact of share repurchases.<\/p>\n
Our Take on SNY\u2019s Q1 Results <\/p>\n
Sanofi\u2019s first-quarter results were strong as it beat estimates for earnings as well as sales. Both sales and earnings rose in a double-digit range at CER in the quarter. Higher sales of Dupixent and contributions from new products like Altuviiio and Ayvakit drove top-line growth. Vaccine sales also improved in the quarter, benefiting from the inclusion of Heplisav-B. Dupixent continues to be the key top-line driver with global sales rising above \u20ac4 billion for the past three consecutive quarters.<\/p>\n
Sanofi\u2019s shares were up more than 4% in pre-market trading in response. Sanofi\u2019s stock has declined 12.4% in the past year against the industry\u2019s increase of 12.9%.<\/p>\n
Zacks Investment Research <\/p>\n
Image Source: Zacks Investment Research<\/p>\n
Sanofi is seeing a good uptake of its new medicines and vaccines. Altuviiio achieved blockbuster sales in 2025 and Ayvakit is expected to become the next blockbuster drug in 2026. Last year, Sanofi launched Qfitlia and Wayrilz. Sales of Sanofi\u2019s newly launched drugs and vaccines rose almost 50% in the first quarter.<\/p>\n
Some potential blockbuster assets in phase III development are amlitelimab (anti-OX40L mAb for moderate-to-severe atopic dermatitis) and frexalimab (anti-CD40L mAb for multiple sclerosis). Regulatory applications for amlitelimab and frexalimab are planned in the second half of 2026 and 2027, respectively.<\/p>\n
Sanofi has also been active on the M&A front. In February, it completed the previously announced acquisition of vaccine maker Dynavax Technologies for a total equity value of approximately $2.2 billion. Last year, it acquired Blueprint Medicines, which has expanded its presence in rare immunological diseases and Vigil Neuroscience, which expanded its early-stage pipeline in neurology. The company has also got a new chief executive officer, Bel\u00e9n Garijo, who will replace Paul Hudson, effective April 29, 2026.<\/p>\n
SNY\u2019s Zacks Rank <\/p>\n
Sanofi currently has a Zacks Rank #3 (Hold). You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here.<\/p>\n
Sanofi Price and Consensus Sanofi Price and Consensus <\/p>\n
Sanofi price-consensus-chart | Sanofi Quote<\/p>\n
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report<\/a><\/p>\n Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report<\/a><\/p>\n Sanofi (SNY) : Free Stock Analysis Report<\/a><\/p>\n AstraZeneca PLC (AZN) : Free Stock Analysis Report<\/a><\/p>\n This article originally published on Zacks Investment Research (zacks.com).<\/a><\/p>\n